Gender-dependent differences in the efficacy and safety of Boceprevir triple therapy in German real-life
P Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, C John, P Geyer, B Weber, T Witthöft, A Herrmann, M Hoesl, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer · Zeitschrift für Gastroenterologie · 2015 · Heft 08
Bibliografische Angaben
Zusammenfassung
Background: Since 2011, triple therapy with the HCV protease inhibitor boceprevir (BOC) is widely used as standard of care for patients (pts) with chronic HCV G1 infection. Until now, there is limited information about the efficacy and safety of BOC triple therapy in clinical practice and whether differences occur between female and male pts. Methods: From April 2012 until January 2014, 536 pts with HCV G1 infection were recruited in the ongoing NOVUS observational study by 97 practices and hospitals in Germany. Pts were treated with pegylated interferons (PegIFN) and ribavirin (RBV) together with BOC for 24 to…
